DE69625516T2 - Verwendung von il-10 zur wundheilung mit verminderter narbenbildung - Google Patents

Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Info

Publication number
DE69625516T2
DE69625516T2 DE69625516T DE69625516T DE69625516T2 DE 69625516 T2 DE69625516 T2 DE 69625516T2 DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T2 DE69625516 T2 DE 69625516T2
Authority
DE
Germany
Prior art keywords
wounds
modified form
partially modified
healing
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625516T
Other languages
German (de)
English (en)
Other versions
DE69625516D1 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DE69625516D1 publication Critical patent/DE69625516D1/de
Publication of DE69625516T2 publication Critical patent/DE69625516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69625516T 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung Expired - Lifetime DE69625516T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (2)

Publication Number Publication Date
DE69625516D1 DE69625516D1 (de) 2003-01-30
DE69625516T2 true DE69625516T2 (de) 2003-09-25

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625516T Expired - Lifetime DE69625516T2 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Country Status (13)

Country Link
US (2) US6387364B1 (enExample)
EP (1) EP0871473B1 (enExample)
JP (1) JP4050317B2 (enExample)
AT (1) ATE229814T1 (enExample)
AU (1) AU719089B2 (enExample)
CA (1) CA2229078C (enExample)
DE (1) DE69625516T2 (enExample)
DK (1) DK0871473T3 (enExample)
ES (1) ES2187665T3 (enExample)
GB (1) GB2304047A (enExample)
PT (1) PT871473E (enExample)
WO (1) WO1997005894A1 (enExample)
ZA (1) ZA966744B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505219A (ja) * 1996-12-04 2001-04-17 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター 創傷の治癒および線維症の治療
WO1998033516A1 (en) * 1997-02-05 1998-08-06 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
AU6951300A (en) * 1999-09-08 2001-04-10 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
KR20150072458A (ko) 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
MX2010010431A (es) * 2008-03-25 2010-11-25 Paloma Pharmaceuticals Inc Metodos para tratar desordenes fibroticos.
CN102256625B (zh) 2008-12-17 2013-11-20 默沙东公司 单和双peg il10的生产和用途
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20140112898A1 (en) * 2011-03-31 2014-04-24 President And Fellows Of Harvard College Unique population of regulatory t cells that regulate tissue regeneration and wound healing
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
EP3341012B1 (en) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0280560B1 (en) 1987-02-27 1994-05-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Membrane structure coated with low pI protein and methods of making and using
EP0454736A4 (en) * 1989-01-20 1993-05-12 The University Of Melbourne Fibrinolysis
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
ATE171625T1 (de) 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
ES2085003T3 (es) * 1991-01-10 1996-05-16 Schering Corp Uso de il-4 para mejorar la fase reparadora de la curacion y restaño de heridas y para mejorar la curacion de heridas infectadas y las heridas de mamiferos diabeticos.
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU8647991A (en) 1991-08-26 1993-03-16 State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
NZ269663A (en) 1993-07-26 1997-09-22 Schering Corp Agonists and antagonists of il-10
AU710153B2 (en) * 1994-03-29 1999-09-16 Renovo Limited Wound healing
EP1621206A1 (en) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Also Published As

Publication number Publication date
US6387364B1 (en) 2002-05-14
ZA966744B (en) 1998-02-09
JPH11510505A (ja) 1999-09-14
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
JP4050317B2 (ja) 2008-02-20
EP0871473B1 (en) 2002-12-18
EP0871473A1 (en) 1998-10-21
DK0871473T3 (da) 2003-04-14
CA2229078C (en) 2010-04-20
ES2187665T3 (es) 2003-06-16
AU719089B2 (en) 2000-05-04
GB2304047A (en) 1997-03-12
GB9516287D0 (en) 1995-10-11
PT871473E (pt) 2003-03-31
CA2229078A1 (en) 1997-02-20
WO1997005894A1 (en) 1997-02-20
US7052684B2 (en) 2006-05-30
DE69625516D1 (de) 2003-01-30
ATE229814T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
DE69625516T2 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DE3782358T2 (de) Wundheilende zusammensetzung.
DE69002795T2 (de) Stabilisierte, den epidermalen Wachstumsfaktor enthaltende Mittel.
EP1526867B1 (de) Erythropoietin in subpolycythämischen dosen
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE69231486T2 (de) Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und -regenerierung
DE69228949T2 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE60130008T2 (de) Proteinkombinationen zur heilung von wunden
DE69119879T2 (de) Epitheliocytenwachstumsbeschleuniger
EP0203580B1 (de) Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen
DE69033703T2 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
DE69031218T2 (de) Wundheilung
DE69633396T2 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
DE69009748T2 (de) Fgf enthaltende stabilisierte zubereitungen.
DE3853721T2 (de) Verwendungen von rekombinantem koloniestimulierendem faktor-1.
DE69634905T2 (de) Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung
DE69211723T2 (de) Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren
EP0493662B1 (de) Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge
DE60116982T2 (de) Verwendung einer Stutenmilchfraktion ausgewählt aus Magermilch, Molke und Natriumcaseinat mit entzündungshemmender Wirkung
AT403434B (de) Topische zusammensetzung zur beschleunigung der wundheilung
DE69607854T2 (de) Sphingosylphosphorylcholin als wirkstoff zur wundheilung
DE69133074T2 (de) Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten
DE3883252T2 (de) Örtliche wundheilmittel, die interleukin-1-proteine enthalten.
DE69903166T2 (de) Verfahren zur gewinnung von fibrillin aus cnidaria und entsprechende kosmetische zusammensetzungen
DE69916022T2 (de) Methode zur Verwendung von IL-11 zur Verstärkung der zellvermittelten Immunität zur Behandlung verschiedener viraler und parasitärer Infektionen und Krebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition